391 results about "Plasma sample" patented technology

The invention relates to a detection method performed on a maternal serum or plasma sample from a pregnant female, which method comprises detecting the presence of a nucleic acid of foetal origin in the sample. The invention enables non-invasive prenatal diagnosis including for example sex determination, blood typing and other genotyping, and detection of pre-eclampsia in the mother.

Described is a method for calibrating a spectrophotometric apparatus which is used to measure analytes in plasma and/or serum samples based on the calibration of a First Apparatus, and for recalibrating such apparatus, including recalibration of the First Apparatus all using synthetic calibrators. These apparatus use absorption of radiation to measure analytes in serum or plasma samples. The method described includes using synthetic calibrators which are submitted to the First Apparatus for measurement and compared with measurements of similar calibrators in a Second Apparatus and using the comparison to derive concentrations of analytes in samples measured on the Second Apparatus. As an alternative to making all apparatus identical, in terms of wavelength calibration, the absorbances of all apparatus should be mapped onto a standard set of wavelengths.

The invention provides methods and reagents for diagnosing colorectal cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated. In some embodiments, the CNA biomarkers are polynucleotide fragments, e.g., DNA fragments, that are present at an elevated level in blood, e.g., in a serum or plasma sample, of a colorectal cancer patient in comparison to the level in blood, e.g., a serum or plasma sample, obtained from a normal individual who does not have colorectal cancer.

This disclosure provides a method to capture, detect, characterize and quantify human exosomes in small volumes of human body fluids by using a sandwich ELISA test. This method allows a full characterization of an exosome preparation, thus providing a tool to distinguish a disease-related condition from a healthy state, by the use of a non-invasive assay. In fact, this method may be useful in screening, diagnosis and prognosis of tumors, with a simple plasma sample. At the same time measurement of circulating exosomes may provide information on the level of tumor mass present in a patient. The method provided here is suitable to evaluate presence of some infectious and/or transmissible agents, such as viral proteins or prion proteins, within circulating exosomes.

The invention relates to an application of inductively coupled plasma mass spectrometry in drug testing of hemin. A method for measuring concentration of stable isotope iron in animal plasma is carried out by an ICP-MS (Inductively Coupled Plasma Mass Spectrometry) method and comprises the following steps of: providing an inductively coupled plasma source mass spectrometer; determining operating conditions of the ICP-MS; providing stable isotope iron powder, marked hemin, internal standard elements and the like; preparing standard solution and internal standard solution; preparing ICP-MS diluent; establishing a standard curve; measuring the stable isotope iron concentration in the plasma; and adding the ICP-MS diluent into a sample tube containing animal plasma sample containing iron, mixing uniformly and putting the sample tube into a refrigerator to be refrigerated, and determining the concentration of the iron in the plasma by the obtained standard curve. The application of the inductively coupled plasma mass spectrometry in the drug testing of the hemin has well performances, e.g., the method has well quantification lower limit, accuracy, absolute recovery test, sample stability, medium effect and quality control requirement, and can be taken as a content measurement method for analyzing the content of the stable isotope iron in a biological sample such as the plasma.

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

The invention discloses an experimental method for animal model depression degree evaluation based on metabonomics. The experimental method comprises the following steps: comprehensively and accurately determining endogenous small molecule metabolites in a biological sample by utilizing a metabonomics platform based on high-resolution mass spectrum, screening different metabolites among different samples and different groups according to the obtained metabolic spectrum data by combining a single-variable multi-variable statistical method, utilizing a common different metabolite among three samples, comparing correlation of compounds in a blood plasma sample and a brain tissue sample, and taking a comparison result as a basis of reflecting change of metabolome in brain tissues by utilizing a blood plasma marker; meanwhile, taking a model group and a control group as a training set to construct a model and an administration group as predication capability of a validation set test model, which is an index for evaluating the depression degree by utilizing the change of the blood plasma metabolome. The experimental method disclosed by the invention can be used for solving the problems that the traditional behavioral experiment has many uncontrollable factors, preparation is relatively complex and animal subjectivity is stronger.

The invention discloses a method for measuring blood concentration of paraquat. The method comprises the following steps of: (1) pretreating a sample, namely adding aqueous solution of an internal standard substance and a protein precipitation agent acetonitrile into a plasma sample, performing whirl mixing, centrifuging and sampling supernatant; (2) separating the sample, namely adopting a universal C18 liquid chromatographic column, and using an ion pairing agent in an acid mobile phase, wherein the acid mobile phase is mixed solution of 3mmol.L<-1> aqueous solution of sodium dodecyl sulfate, 0.2 percent of aqueous solution of trifluoroacetic acid, acetonitrile and water; and (3) detecting by using a diode array detector, namely detecting by using the diode array detector at a detectionwavelength of 250 to 260nm, measuring peak areas of the internal standard substance and the paraquat, and calculating the blood concentration of the paraquat through least square method linear regression. The plasma sample is easy and convenient to pretreat, the detection process is sensitive and rapid, toxic substances and the blood concentration thereof can be rapidly determined in actual application, and the method is high in clinical application value.

The invention discloses a high-flux detection method of a circulating DNA liver cancer driver gene. According to the method, a mutant gene which is the most common of the existing liver cancer is selected and combined with a second-generation high-flux sequencing technology to more comprehensively detect a gene mutant condition of the liver cancer. Since a blood plasma sample of a patient is adopted, the method can greatly reduce the detection injury of a patient; secondly, the whole-exome detection is performed on 75 liver cancer genes, the method is more comprehensive compared to the detection method based on real-time PCR and first-generation Sanger sequencing technology; and since only 75 genes are detected, the sample can be detected in a greater sequencing depth, so that the detection precision can reach 0.1 percent. Therefore, a reference can be provided for more and better individual precision therapeutic schemes of the patient.

The invention discloses probes, primers, a detection system and a kit for detecting mutations of an EGFR gene, and the probes and the primers have the sequences of SEQ ID NO.1 to SEQ ID NO.24. The invention is characterized in that (1), the amplification efficiency is greatly improved to a largest extent; (2) the sensitivity is high, and the detection sensitivity can reach 0.2%; (3) compared with a digital PCR method, operations are simple, the cost is saved, and the clinical application scope is wide; (4) plasma samples with large reaction volume are detected, the DNA sampling quantity of the plasma samples becomes larger, the system is more stable, and the detection rate of the plasma samples is increased; (5) 25 mutations of the EGFR gene can be detected simultaneously in three reaction tubes, and results are intuitive and clear; (6) the detection speed is fast, and consumed time is only 1/2 that of the digital PCR; and (7) a detection method can detect peripheral blood samples, has convenient sampling, and can dynamically monitor curative effect of EGFR-TKI drugs on patients.

The invention discloses a kit and method for quantitatively detecting five fat-soluble vitamins in blood plasma. The kit comprises a fat-soluble vitamin calibrator, an isotope mixed standard substance, a fat-soluble vitamin quality control substance, an instrument quality control substance and a mobile phase additive. According to the invention, a solid-phase support liquid-liquid extraction method is adopted and is matched with an automatic pipetting station, so a sample pretreatment method is greatly simplified, and the aim of simultaneously and accurately detecting the five fat-soluble vitamins at high flux and high speed is fulfilled by combining a liquid chromatography-tandem mass spectrometry method. According to the invention, during the detection of a peripheral blood plasma sample, five fat-soluble vitamins can be quantified at a time only by about 250 microliters of plasma sample; moreover, due to a fact that the pretreatment method is simple and quick, the operation time issaved, the content of the fat-soluble vitamins in a human body can be effectively diagnosed and detected according to the indexes, and diseases caused by lack or excess of the fat-soluble vitamins canbe prevented and diagnosed in time. Therefore, the kit and method have extremely high application values in clinical, health examination and scientific research.

The invention relates to a method for detecting the liquid quality of an antipsychotic drug in serum or plasma and pretreatment of a specific purification material of the antipsychotic drug. The method comprises the following steps: a serum or plasma sample is subjected to protein precipitation by a certain proportion of organic reagents; a supernatant obtained through centrifugal precipitation ispretreated with a specific purification material to obtain a purified sample solution, the purified sample solution is subjected to liquid chromatography-tandem mass spectrometry detection and analysis, and eight antipsychotic drugs including olanzapine, clozapine, quetiapine, aripiprazole, flupiperidinol, risperidone, pariperidone and ziprasidone in serum or plasma are detected at the same time.The pretreatment of the specific purification material is a mixed solid-phase extraction column taking silica gel as a matrix, and the blood is purified by the specific purification material, so thatthe interference of the matrix in the blood can be removed, the matrix effect of eight antipsychotic drugs can be improved, and the recovery rate of the antipsychotic drugs can be better ensured.

The invention relates to a serum or plasma sample diluent and application thereof. Particularly, the serum or plasma sample diluent comprises a buffer solution (a), albumin (b) with content of 10-100g/L, alkaline chloride (c) and an optional emulsifier (d), wherein the pH value of the diluent is 6.0-8.0. Compared with the existing human negative mixed serum or plasma and calf serum diluent, the diluent provided by the invention has the characteristics of precise and accurate detection result and long-time stable preservation. The invention also discloses a detection kit containing the diluent and application of the diluent in immunoassay.

The invention discloses probes, primers and a kit for detecting a T790M mutation of an EGFR gene. The probes and the primers have the following sequence: SEQ ID NO: 01 to SEQ ID NO. 07. The probes, the primers and the kit have the following benefits: (1) SNP sites on the primers are designed as G/A merged basic groups, so that all efficiencies are compatible, and the amplification efficiency is improved; (2) the sensitivity is high, that is, the detection sensitivity can reach 2 permillage; (3) compared with those adopting a digital PCR method, the operation is simple, the cost is reduced, and the clinical application range is wide; (4) through blood plasma sample detection with a large reaction volume, the DNA loading quantity of blood plasma samples is increased, the detection system is more stable, and the detection rate of the blood plasma samples is improved; (5) the detection speed is high, that is, the detection process can be completed within only 120 minutes, and the time consumed in the detection process is only a half of that consumed according to the digital PCR method; (6) the probes, the primers and the kit, provided by the invention, can be utilized for detecting peripheral blood samples, so that convenient sampling and dynamic detection can be realized.

The invention discloses a real-time fluorescence nucleic acid isothermal amplification detection kit for HCV (hepatitis C virus). The detection kit specifically comprises a capture probe, HCV primers, an HCV detecting probe, M-MLV reverse transcriptase, T7RNA polymerase and the like, wherein the HCV primers include a T7 primer and an nT7 primer. By the detection kit which is high in detection efficiency, high in accuracy and promising in application prospect, nucleic acid amplification detection can be performed on serum or plasma samples containing hepatitis C viruses in a high-specificity, high-sensitivity, low-pollution and fast manner, and 6 genotypes of HCV can be detected.

The invention discloses a solid-phase extraction method of steroid hormones in serum or plasma, which comprises the following steps: (1) adding an internal standard working solution into a serum or plasma sample, uniformly performing mixing and standing, adding methanol to precipitate proteins, adding water to regulate the volume ratio of an organic phase to a water phase to 1: 2, and performing centrifuging to obtain a pretreated sample; and (2) activating the solid-phase extraction plate holes, adding the sample pretreated in the step (1) into the activated solid-phase extraction plate holes, sequentially performing treating by using a leacheate and an eluent, collecting fractions treated by the eluent by using a collecting plate, adding water into the collecting plate holes, carrying out vortex uniform mixing, and sealing a film. By adopting the extraction method provided by the invention, 19 steroid hormones containing the whole steroid hormone metabolic pathway can be obtained atthe same time through one-time solid-phase extraction treatment.

The invention discloses an immunochromatography test kit using a novel whole blood sample pad processing method and relates to a novel whole blood sample pad processing method, an immunochromatography kit prepared by using the same, and a test method of the immunochromatography kit. The whole blood sample pad of the invention can be realized by uniformly spreading a non-bioactive prothrombin activator and solution containing phospholipids and calcuium ions Ca<2+> on a sample pad and can be widely used in immunochromatography test kits capable of synchronously testing whole blood/ serum/plasma samples. The method can make the preparation and production process of immunochromatographic reagents using whole blood as a test sample simple, convenient and effective and has the advantages of low cost, small sample dosage, high test speed and the like at the same time.

The invention provides a blood-based noninvasive early lung cancer detection method, which investigates a panel of miRNA levels in a blood or plasma sample. The panel of miRNA includes miR-17, miR-21, miR-24, miR-106a, miR-125b, miR-128, miR-155, miR-182, miR-183, miR-197, miR-199b, miR-203, miR-205, miR-210, miR-221, and a combination thereof. Preferably, the panel of miRNA may include miR-21, miR-128, miR-155, miR-182, miR-183, and miR-197. The inventive method can not only detect stage I lung cancer patients with high accuracy, but also differentiate between all stages of lung cancer patients and lung cancer-free individuals, metastatic and non-metastatic lung cancer patients and monitor the significant changes of miRNA levels during chemotherapy.

Described is a device that is able to distinguish different nucleic acid concentrations in whole blood or plasma sample directly in under 10 min. By using this device, cell-free DNA in whole blood or plasma can be quantified without extensive sample preparation. The device contains a sample channel, an accumulation channel and a pair of electrodes. Optionally, the device includes power supply connected to the electrodes for generating an electric field to move the DNA from the sample channel to the collection channel, and a sensor to quantify the amount of cell free DNA in the collection channel. Also provided are methods for providing a prognosis for a subject with sepsis or suspected of having sepsis comprising quantifying nucleic acid concentrations in a sample from a subject using a device as described herein.